Thermo Fisher Scientific Inc. (NYSE:TMO) is Cohen Capital Management Inc.’s 2nd Largest Position

Cohen Capital Management Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% in the 1st quarter, HoldingsChannel reports. The firm owned 57,598 shares of the medical research company’s stock after purchasing an additional 70 shares during the period. Thermo Fisher Scientific comprises approximately 4.9% of Cohen Capital Management Inc.’s holdings, making the stock its 2nd largest position. Cohen Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $28,661,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company’s stock valued at $17,297,426,000 after purchasing an additional 196,864 shares in the last quarter. Capital World Investors lifted its position in shares of Thermo Fisher Scientific by 1.1% during the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company’s stock valued at $4,905,812,000 after acquiring an additional 104,343 shares during the period. Geode Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company’s stock worth $4,075,540,000 after acquiring an additional 197,442 shares in the last quarter. Norges Bank purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $3,149,754,000. Finally, Northern Trust Corp raised its holdings in Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock worth $2,034,107,000 after purchasing an additional 455,004 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company’s stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.0%

Shares of TMO stock opened at $435.02 on Monday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The firm’s 50-day simple moving average is $409.39 and its 200-day simple moving average is $475.87. The firm has a market cap of $164.22 billion, a P/E ratio of 25.51, a PEG ratio of 2.31 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the company earned $5.11 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. UBS Group cut Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and dropped their price target for the company from $500.00 to $460.00 in a research report on Tuesday, July 8th. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday. Evercore ISI cut their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, May 21st. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $600.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.